fertcommon.blogg.se

Prior accomplishments include supporting the regulatory submission and FDA approval of PLENVU ®, Dex圜u ®, and Solesta ®. Previously, he held leadership roles within early-stage biotechnology companies as well as large pharmaceutical companies, including Icon Bioscience, Oceana Therapeutics, The Medicines Company, and Esprit Pharma. He most recently served as Chief Medical Officer at Salix Pharmaceuticals, where he provided leadership and expertise to program teams focused on the development of GI therapeutics, including amiselimod, next generation Xifaxan ® formulations, ENVIVE™, and other GI and microbiome focused programs. Franklin has more than 20 years of experience as a general surgeon and biopharmaceutical executive, with deep expertise spanning clinical development, regulatory strategy, medical affairs, and product commercialization. Howard Franklin, MD, MBA, Senior Vice President, Late-Stage Development and GI Therapeutic Area Leadĭr. Batycky earned a bachelor’s degree in Toxicology and Pharmacology and a PhD in Toxicology from the School of Pharmacy, University of London, UK. Her accomplishments include supporting the successful development of Feraheme ®, Inbrija ®, and Vivitrol ®. Prior to this, she held increasing responsibilities at CombinatoRx, Synta Pharmaceuticals, Alkermes and GSK. Previously, she held leadership roles at Akashi Therapeutics, Warp Drive Bio, and AMAG Pharmaceuticals. Batycky most recently served as Chief Development Officer at Ohana Biosciences, where she oversaw regulatory, manufacturing, quality and clinical operations.

Batycky has more than 20 years of international biopharmaceutical industry experience, spanning from early discovery to product approval. She has led development teams across a broad range of therapeutic areas including oncology, CNS disorders, inflammatory diseases and reproductive health, utilizing multiple modalities including small molecules, biologics, devices and combination products. He earned a BS in Biology from Eastern Nazarene College and an MBA from Boston University.Īlka Batycky, PhD, Chief Development Officerĭr. Prior accomplishments include supporting development programs and regulatory submissions for Replagal ® & VPRIV ®. Gillis held manufacturing and company leadership roles of increasing responsibility at Alexion, Sanofi (Genzyme), Lonza, and Amgen. He most recently served as Vice President of Manufacturing and Supply at Rubius Therapeutics, where he led the development and execution of the company’s supply chain strategy with a focus on commercial launch. Gillis has more than 20 years of experience across operations management, supply chain, global program leadership, strategic product and portfolio life cycle management, and global product quality management in the biotechnology industry. difficile, prepare to launch our next programs into the clinic, and continue to make progress across multiple discovery-stage programs that offer exciting new opportunities to leverage our microbiome therapeutics platform.”īryan Gillis, MBA, Chief Technology Officer “We look forward to leveraging their expertise and insights as we advance our Phase 3 program in recurrent C. With Bryan’s manufacturing and operations experience, Alka’s broad drug development expertise, and Howard’s experience leading late-stage development and commercialization of novel GI therapeutics, each of these new executives will further strengthen Finch’s capabilities in areas that will be key to the next phase of our growth,” said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. “We are delighted to welcome Bryan, Alka and Howard to the team, three accomplished leaders who each bring deep industry expertise to Finch. (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced the appointment of Bryan Gillis, MBA, to Chief Technology Officer, Alka Batycky, PhD, to Chief Development Officer, and Howard Franklin, MD, MBA, to Senior Vice President, Late-Stage Development and Gastrointestinal (GI) Therapeutic Area Lead. 10, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc.